NBIX director exercises 3,318 RSUs into shares

NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised restricted stock units into common shares.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. These RSUs were granted on May 21, 2025 and were fully vested. Following the transaction, Pops directly holds 37,798 shares of Neurocrine Biosciences common stock, reflecting a routine equity compensation event with no open-market buying or selling.

Insider Trade Summary

3,318 shares exercised/converted

Exercise 2 txns

Insider POPS RICHARD F

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	3,318	$0.00	$0.00
Exercise	Common Stock	3,318	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 37,798 shares (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
2. F2. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Key Figures

RSUs exercised: 3,318 units Common shares acquired: 3,318 shares Post-transaction holdings: 37,798 shares +1 more

4 metrics

RSUs exercised 3,318 units Restricted Stock Units converted to common stock on May 21, 2026

Common shares acquired 3,318 shares Shares received from RSU conversion at $0.00 per share

Post-transaction holdings 37,798 shares Common stock directly held by Richard F. Pops after the transaction

Exercise price $0.00 per share Price for RSU conversion into common stock

Key Terms

Restricted Stock Unit, derivative security, Form 4

3 terms

Restricted Stock Unit financial

"The Form 4 lists a derivative transaction in "Restricted Stock Unit"."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"The M code is described as "Exercise or conversion of derivative security"."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 regulatory

"This insider transaction is disclosed on a Form 4 insider filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NBIX director Richard F. Pops report?

Richard F. Pops reported exercising 3,318 Restricted Stock Units into 3,318 shares of Neurocrine Biosciences common stock. The transaction reflects conversion of equity compensation rather than an open-market stock purchase or sale, and is coded as an exercise of a derivative security.

How many Neurocrine Biosciences (NBIX) shares does Richard F. Pops hold after this Form 4?

After this transaction, Richard F. Pops directly holds 37,798 shares of Neurocrine Biosciences common stock. This total includes the 3,318 shares received upon conversion of fully vested Restricted Stock Units, as reflected in the post-transaction ownership reported in the Form 4 filing.

Were the NBIX shares in this Form 4 bought or sold on the open market?

No open-market buy or sell occurred. The Form 4 shows a derivative exercise where 3,318 Restricted Stock Units converted into 3,318 common shares at an exercise price of $0.00 per share, representing routine settlement of equity compensation, not discretionary trading.

What does the M transaction code mean in the NBIX Form 4 filing?

The M code indicates an exercise or conversion of a derivative security. In this case, 3,318 Restricted Stock Units converted into 3,318 shares of Neurocrine Biosciences common stock, with no sale of shares and no tax-withholding disposition reported in the transaction summary.

When were the Restricted Stock Units in this NBIX Form 4 originally granted?

The Restricted Stock Units were granted on May 21, 2025. Footnotes explain that each RSU represents the right to receive one share of Neurocrine Biosciences common stock upon vesting, and this award was fully vested before being converted into common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 07:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POPS RICHARD F

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		M		3,318	A	$0	37,798	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0(1)	05/21/2026		M			3,318	(2)	(2)	Common Stock	3,318	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)